Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33. https://doi.org/10.1016/S1470-2045(10)70207-2.
Article PubMed PubMed Central Google Scholar
Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial. JAMA. 2017;318(10):918–26. https://doi.org/10.1001/jama.2017.11470.
Article PubMed PubMed Central Google Scholar
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10. https://doi.org/10.1016/S1470-2045(14)70460-7.
Article PubMed PubMed Central Google Scholar
de Boniface J, Tvedskov TF, Rydén L, Szulkin R, Reimer T, Kühn T, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med. 2024;390:1163–75.
Reimer T, Stachs A, Veselinovic K, Kühn T, Heil J, Polata S, et al. Axillary surgery in breast cancer — primary results of the INSEMA trial. N Engl J Med. 2025;392:1051–64.
Park KU, Somerfield MR, Anne N, Brackstone M, Conlin AK, Couto HL, et al. Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2025;43(14):1720–41. https://doi.org/10.1200/JCO-25-000.
Article CAS PubMed Google Scholar
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thu¨rlimann B, Senn H-J, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Annal Oncol. 2011;22:1736–47. https://doi.org/10.1093/annonc/mdr304.
Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allisonet KH, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6):691–722. https://doi.org/10.6004/jnccn.2022.0030.
Shimoi T, Nagai SE, Yoshinami T, Takahashi M, Arioka H, Ishihara M, et al. The Japanese breast cancer society clinical practice guidelines for systemic treatment of breast cancer, 2018 edition. Breast Cancer. 2020;27(3):322–31.
Article PubMed PubMed Central Google Scholar
National Cancer Institute. Physician Data Query (PDQ). Lymphedema – health professional version. 2019. Accessed at https://www.cancer.gov/about cancer/treatment/side-effects/lymphedema/lymphedema-hp-pdq on July 12, 2021.
National Comprehensive Cancer Network (NCCN). Practice guidelines in oncology: breast cancer. Version 5. 2021. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf on July 12, 2021.
Cote R, Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, et al. ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. J Clin Oncol. 2010. https://doi.org/10.1200/jco.2010.28.18_suppl.cra504.
Van Zee KJ, Manasseh D-M, Bevilacqua JLB, Boolbol SK, Fey JV, Tan LK, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140–51. https://doi.org/10.1245/aso.2003.03.015.
Degnim AC, Griffith KA, Sabel MS, Hayes DF, Cimmino VM, Diehle KM, et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients: a meta-analysis. Cancer. 2003;98(3):2307–15.
Viale G, Maiorano E, Pruneri G, Mastropasqua MG, Valentini S, Galimberti V, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and sentinel node metastasis. Annal Surg. 2005;241(2):319–25. https://doi.org/10.1097/01.sla.0000150255.30665.52.
Bevilacqua JL, Kattan MW, Fey JV, Cody HS 3rd, Borgen PI, Van Zee KJ. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol. 2007;25(24):3670–9. https://doi.org/10.1200/JCO.2006.08.8013.
NCCN Clinical Practice Guidelines in Oncology Breast Cancer Version 4. 2025 https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Loibl S, André F, Bachelot T, Curigliano G, Harbeck N, on behalf of the ESMO Guidelines Committee. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annal Oncol. 2024;35(2):159–82.
Mattes MD, Bhatia JK, Metzger D, Ashamalla H, Katsoulakis E. Breast cancer subtype as a predictor of lymph node metastasis according to the SEER registry. J Breast Cancer. 2015;18(2):143–8. https://doi.org/10.4048/jbc.2015.18.2.143.
Article PubMed PubMed Central Google Scholar
Kim JY, Kim J, Lee HB, Lee YJ, Seong M-K, Paik N, et al. Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to world health organization classification: comparative analysis to invasive carcinoma of no special type. Breast Cancer Res Treat. 2020;184(2):527–42. https://doi.org/10.1007/s10549-020-05861-6.
Qingyang Li HuXu, Bao B, Xie Y, Guo S, Gao Z, et al. Predicting sentinel lymph node metastasis in breast cancer: a study based on the SEER database. Clin Exp Med. 2025;25:82–96. https://doi.org/10.1007/s10238-025-01591-5.
Article CAS PubMed PubMed Central Google Scholar
Solà M, Recaj M, Castellà E, Puig P, Gubern JM, Julian JF, et al. Sentinel node biopsy in special histologic types of invasive breast cancer. J Breast Health. 2016;12(2):78–82. https://doi.org/10.5152/tjbh.2016.2929.
Comments (0)